PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Wagemann, O.* ; Nübling, G.* ; Martínez-Murcia, F.J.* ; Wlasich, E.* ; Loosli, S.V.* ; Sandkühler, K.* ; Stockbauer, A.* ; Prix, C.* ; Katzdobler, S.* ; Petrera, A. ; Hauck, S.M. ; Fortea, J.* ; Romero-Zaliz, R.* ; Jiménez-Mesa, C.* ; Górriz Sáez, J.M.* ; Höglinger, G.* ; Levin, J.*

Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease.

Alzheimers Dement. 21:e70040 (2025)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
INTRODUCTION: Adults with Down syndrome (DS) show increased risk for Alzheimer's disease (AD) due to the triplication of chromosome 21 encoding the amyloid precursor protein gene. Further, this triplication possibly contributes to dysregulation of the immune system, furthering AD pathophysiology. METHODS: Using Olink Explore 3072, we measured ∼3000 proteins in plasma from 73 adults with DS and 15 euploid, healthy controls (HC). Analyses for differentially expressed proteins (DEP) were carried out, and pathway and protein network enrichment using Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and STRING database was investigated. Within DS, the LASSO (least absolute shrinkage and selection operator) feature selection was applied. RESULTS: We identified 253 DEP between DS and HC and 142 DEP between symptomatic and asymptomatic DS. Several pathways regarding inflammatory and neurodevelopmental processes were dysregulated in both analyses. LASSO feature selection within DS returned 15 proteins as potential blood markers. DISCUSSION: This exploratory proteomic analysis found potential new blood biomarkers for diagnosing DS-AD in need of further investigation. HIGHLIGHTS: Inflammatory pathways are dysregulated in symptomatic versus asymptomatic DS. NFL and GFAP are confirmed as powerful biomarkers in DS with clinical and/or cognitive decline. Further circulating proteins were identified as potential blood biomarkers for symptomatic DS.
Impact Factor
Scopus SNIP
Altmetric
11.100
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Alzheimer's Disease ; Down Syndrome ; Biomarker ; Neuroinflammation ; Plasma; Clinical-diagnosis; Biomarker Changes; Dementia; Protein; Neuroinflammation; Individuals; Impairment; Framework; Fetuses; Binding
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 1552-5260
e-ISSN 1552-5279
Zeitschrift Alzheimer's & Dementia
Quellenangaben Band: 21, Heft: 3, Seiten: , Artikelnummer: e70040 Supplement: ,
Verlag Elsevier
Verlagsort New York, NY [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) CF Metabolomics & Proteomics (CF-MPC)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e) A-630700-001
G-505700-001
Förderungen Deutsche Forschungsgemeinschaft
Jerome Lejeune Foundation
VERUM Foundation
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1
Unión Europea
Una Manera de Hacer Europa
DOI 10.1002/alz.70040
WOS ID 001449320600001
Scopus ID 105001041077
PubMed ID 40110647
Erfassungsdatum 2025-05-09
[➜Korrektur melden]